ProMune (CPG 7909, TLR9): Coley Pharmaceutical Group : Synthetic agonist

ProMune Shows Improved Responses in Advanced NSCLC (Coley Pharmaceutical Group)
Press release announces positive results of a randomized, multi-center, Phase II study reported at the February 2005 Keystone meeting that found improved tumor responses when ProMune was combined with chemotherapy compared to standard chemotherapy alone in first-line treatment of advanced NSCLC. [2/05]